ROPALS Trial (2023) — Ropinirole for ALS, Guided by iPSC Drug Discovery
ROPALS — the Ropinirole for ALS trial — is a proof-of-concept study that matters for two reasons that are largely independent of each other. The first is the drug itself: ropinirole, a dopamine D2/D3 receptor agonist widely used in Parkinson's disease and restless legs syndrome, delayed ALS disease progression by an average of 27.9 weeks in a small but properly randomized trial. The second is the method: investigators at Keio University identified ropinirole as a candidate by growing patient-derived iPSC motor neurons, observing what went wrong in the ALS cells, and screening approved drugs for compounds that could fix it. That second story is arguably more important for the future of ALS and PLS drug development than the first-generation finding itself.
What they did
The iPSC Drug Discovery Pipeline
The ROPALS trial began not at a patient's bedside but in a cell culture dish. Led by Satoru Morimoto at the Department of Physiology, Keio University School of Medicine, the research team drew blood from patients with sporadic ALS and reprogrammed it into induced pluripotent stem cells (iPSCs). They then directed those iPSCs to differentiate into motor neurons — the same cell type that ALS destroys.
When they compared ALS-derived motor neurons to healthy control motor neurons under the microscope and in molecular assays, the differences were striking. ALS motor neurons showed distinct abnormalities in cell structure, gene expression patterns, and metabolite concentrations. These were not subtle statistical differences in population averages; they were consistent cell-level signatures of the disease state. Crucially, these signatures appeared in iPSC-derived neurons from multiple different patients, suggesting they reflected genuine disease biology rather than individual genetic noise.
With this cellular disease model in hand, the team screened a library of approved drugs for compounds that reduced the differences between ALS and healthy motor neurons — essentially asking: which known drugs make sick motor neurons look more like healthy ones? Ropinirole emerged as a top hit. Having already cleared drug development and safety approval for Parkinson's disease, it could go directly to a clinical trial without a lengthy de novo safety programme.
The Clinical Trial
Enrollment began in December 2018 at Keio University Hospital in Tokyo. Twenty patients with sporadic ALS entered the trial. The study was single-site, investigator-led, and conducted as a double-blind, placebo-controlled, randomized Phase 1/2a trial — a rigorous design for a first-in-indication test of this compound. Patients were randomized to receive either ropinirole hydrochloride or matched placebo for a 24-week double-blind period, after which an open-label extension was available to all participants.
Primary outcomes were safety and tolerability — the appropriate priorities for a Phase 1/2a trial in a population with a life-limiting illness, where dose-limiting toxicity must be characterized before a larger efficacy trial is warranted. Secondary outcomes assessed therapeutic effects: measures of physical activity, mobility, muscle strength, pulmonary function, and survival.
What they found
Safety and Tolerability
Adverse events were similar in frequency and severity between the ropinirole and placebo groups. The drug was well tolerated, with no excess of serious adverse events in the treatment arm. This is the essential foundation for any further development: ropinirole appears safe to administer to ALS patients at the doses used in this trial.
Clinical Outcomes
Despite the small sample size, several secondary outcome measures favoured ropinirole over placebo. Ropinirole-treated patients were measurably more physically active during the treatment period. Rates of decline in mobility, muscle strength, and respiratory function were slower in the ropinirole group. Survival favoured the treated patients, though interpreting survival differences in a 20-patient trial requires substantial caution.
The headline finding was disease progression: ropinirole delayed progression by an average of 27.9 weeks compared with placebo. For patients and families accustomed to being told that no drug has meaningful effects on ALS disease course, 27.9 weeks — roughly seven months — is not a trivial number. In a disease where the median survival from diagnosis is two to three years, a seven-month delay in progression represents a meaningful fraction of that trajectory.
Individual variability was notable. Some patients on ropinirole responded strongly, with substantial slowing of decline across multiple measures. Others showed little apparent benefit. This variability echoes the responder heterogeneity seen with dalfampridine in MS and with other neurological compounds where patient biology shapes drug response in ways that aggregate group averages obscure.
The iPSC Biomarker Signal
The in-vitro iPSC findings extended into the clinical results in an important way: the degree to which ropinirole reduced the differences between a patient's ALS motor neurons and healthy motor neurons in the lab correlated with that patient's clinical response. Patients whose iPSC-derived motor neurons responded more strongly to ropinirole in culture tended to show greater clinical benefit. This correlation — if it replicates in a larger sample — offers a path toward a predictive biomarker: a way to identify, before starting treatment, which patients are likely to respond. In a disease with as much biological heterogeneity as ALS, a reliable responder biomarker would be a major advance.
Mechanism: More Than Dopamine
Ropinirole is a dopamine D2 and D3 receptor agonist. Its canonical mechanism of action is to compensate for dopaminergic deficiency in the basal ganglia — exactly what makes it effective in Parkinson's disease. But in ALS motor neurons, the drug's cellular protective effects are not fully explained by dopaminergic signalling alone. Motor neurons do not have the same dopamine receptor density as basal ganglia neurons, and the molecular signatures that ropinirole reversed in ALS iPSC motor neurons included mitochondrial function markers, oxidative stress indicators, and gene expression changes that point toward neuroprotective pathways beyond simple D2/D3 agonism.
The investigators' interpretation is that ropinirole has neuroprotective effects in ALS motor neurons that are distinct from, and additional to, its dopaminergic action. The precise molecular cascade has not yet been fully characterised — a common situation with drugs identified by phenotypic screening rather than target-first design. What the data show is that the drug does something protective to ALS motor neurons that goes beyond what its approved mechanism would predict.
Why it matters
For the ALS field, ROPALS demonstrates that iPSC-based drug discovery can identify clinical candidates that produce real signals in real patients. The method — generate patient iPSC motor neurons, characterise their disease signatures, screen approved drugs, test the hits clinically — is a model that other groups are now following. The validation in a randomized clinical trial, however small, is a critical step that most iPSC drug discovery programmes have not yet reached. ROPALS reached it.
For the PLS community, the relevance is more indirect but worth examining carefully. ROPALS was conducted in ALS patients. Its results cannot be extrapolated directly to PLS, and any neurologist considering ropinirole for a PLS patient would be going well beyond the available evidence. The honest statement is: ROPALS shows what ropinirole does in ALS, not what it would do in PLS.
That caveat registered, there is a specific subgroup of PLS patients for whom the ROPALS findings are worth thinking about carefully. A recognized phenotype sometimes described as "PLS-plus" includes PLS patients who develop parkinsonian features — bradykinesia, rigidity, and gait freezing that go beyond what corticospinal tract disease alone would produce. A 2023 BMC Neurology case report described a patient meeting PLS diagnostic criteria who developed prominent parkinsonian features and responded to levodopa therapy, consistent with co-existing dopaminergic deficiency. In patients with this PLS-plus phenotype, the basal ganglia motor loop is doubly compromised: both the cortical output driving it (through UMN disease) and the dopaminergic modulation sustaining it are impaired. Ropinirole's mechanism directly addresses the dopaminergic component.
More broadly, the compensatory circuits framework for PLS argues that the basal ganglia motor loop is one of the systems that walking-capable PLS patients depend on as their corticospinal function declines. If that is correct — and the argument is developed fully on the Targeting Compensatory Circuits page — then dopaminergic enhancement of basal ganglia function is a rational target even in PLS patients without classical parkinsonian features. ROPALS does not prove this extrapolation, but it makes the case that the drug is safe, available, cheap, and active in at least one motor neuron disease context.
The practical advantages of ropinirole are substantial. It is off-patent, inexpensive, and available as a generic in most countries including France. Its safety profile has been established over decades of Parkinson's disease and restless legs syndrome use, in populations that include elderly patients with multiple comorbidities. The dose required for ALS in the ROPALS trial is within the normal Parkinson's disease dosing range. Unlike experimental biologics, a neurologist who decides to trial ropinirole in a PLS patient can do so with a clear pharmacovigilance record and a manageable adverse effect profile — the main concerns being orthostatic hypotension, somnolence, and impulse control changes that are well characterised in the Parkinson's literature.
Limitations
The central limitation of ROPALS is its size. Twenty patients in a 1:1 randomization means approximately 10 per arm. At that scale, a 27.9-week progression difference could be driven by two or three individual outliers. The confidence intervals around the effect estimate are wide, and the result needs to be replicated in a larger, multi-site, adequately powered trial before drawing firm efficacy conclusions. The investigators and the field are clear about this — ROPALS is explicitly designed as a proof-of-concept and safety/tolerability study, not a definitive efficacy demonstration.
The single-site design at Keio University Hospital introduces selection bias. ALS patients at a tertiary academic centre with a specific iPSC drug discovery research programme may differ in important ways from the broader ALS population. Genetic background (the study was conducted in Japan in a predominantly Japanese population), disease stage selection, and referral patterns all warrant consideration when generalizing.
The mechanism remains incompletely characterised. Neuroprotective effects in iPSC motor neurons that extend beyond D2/D3 agonism are intriguing but unexplained. Without understanding the precise pathway, optimising dose, timing, and combination strategies is difficult.
No PLS-specific trial of ropinirole exists. The extrapolation from ALS to PLS is biologically motivated but clinically unvalidated.
How this connects
ROPALS sits at the intersection of two themes relevant to PLS: the potential for approved neurological drugs to show neuroprotective or compensatory circuit-enhancing effects in motor neuron disease, and the emerging iPSC-based approach to patient-specific drug discovery that may eventually produce PLS-targeted compounds. The basal ganglia compensation hypothesis — explored in the Targeting Compensatory Circuits page — provides the theoretical bridge between ropinirole's mechanism and its potential relevance to walking-capable PLS patients.
For a complementary walking-targeted approach with more direct PLS trial evidence, see the dalfampridine Cornell trial. For the broader landscape of drug trials relevant to PLS, the Drug Trials Hub organises the evidence by mechanism and design quality. The MIROCALS IL-2 trial covers another neuroprotective approach that has reached Phase 2/3 in ALS.
Citation
Morimoto S, Takahashi S, Ito D, Fukushima K, Saya H, Suzuki N, Aoki M, Okano H, et al. Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery. Cell Stem Cell. 2023;30(6):766–780.e9. doi:10.1016/j.stem.2023.04.017